Drugs / SCTA01C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05156645 | Jan → Dec 2022 | COVID-19 | Sinocelltech Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTA01C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156645 ↗ |
| Modality | Monoclonal antibody | “Anti-SARS-CoV-2 Monoclonal Antibody Combination (SCTA01C and SCTA01)” NCT05156645 ↗ |